Regulation of platelet biogenesis: Insights from the May-Hegglin anomaly and other MYH9-related disorders

Journal of Thrombosis and Haemostasis

Volumn 7, Issue SUPPL. 1, 2009, Pages 272-276

  Chen, Z ^a,b   Shivdasani, Ramesh A ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Megakaryocyte May Hegglin anomaly; Myosin IIA; Platelet

Indexed keywords

BETA TUBULIN; GENE PRODUCT; INTERLEUKIN 6; MYOSIN IIA; MYOSIN LIGHT CHAIN; PROTEIN MYH9; RHO FACTOR; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR NF E2; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

BIOGENESIS; CELL MATURATION; CELL MIGRATION; CYTOSKELETON; DIMERIZATION; GENE DISRUPTION; GENE MUTATION; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; MAY HEGGLIN ANOMALY; MEGAKARYOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION; THROMBOCYTE VOLUME; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

BLOOD PLATELET DISORDERS; HUMANS; MOLECULAR MOTOR PROTEINS; MYOSIN HEAVY CHAINS; MYOSIN LIGHT CHAINS; NONMUSCLE MYOSIN TYPE IIA; THROMBOPOIESIS;

EID: 67849126835     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03425.x     Document Type: Review

References (34)

1. May R. Leukocyteneinschlusse. Dtsch Arch Klin Med 1909; 96: 1-6.
2. Hegglin R. Simultaneous constitutional changes in neutrophils and platelets. Helv Med Acta 1945; 12: 439-40.
3. Epstein CJ, Sahud MA, Piel CF, Goodman JR, Bernfield MR, Kushner JH, Ablin AR. Hereditary macrothrombocytopathia, nephritis and deafness. Am J Med 1972; 52: 299-310.
4. Peterson LC, Rao KV, Crosson JT, White JG. Fechtner syndrome-a variant of Alport's syndrome with leukocyte inclusions and macrothrombocytopenia. Blood 1985; 65: 397-406.
5. Greinacher A, Nieuwenhuis HK, White JG. Sebastian platelet syndrome: A new variant of hereditary macrothrombocytopenia with leukocyte inclusions. Blut 1990; 61: 282-8.
6. Kelley MJ, Jawien W, Ortel TL, Korczak JF. Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly. Nat Genet 2000; 26: 106-8.
7. Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, Lo Nigros C, Gaiggeri GM, Ravazzolo R, Savino M, Del Vecchio M, d'Apolito M, Iolascon A, Zelitnte LL, Savoia A, Balduini CL, Noris P, Magrini U, Belletti S, Heath KE, Babcock M, et al. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. Nat Genet 2000; 26: 103-5.
8. Kunishima S, Matsushita T, Kojima T, Amemiya N, Choi YM, Josika N, Inoue M, Jung Y, Mamiya S, Matsumoto K, Miyajima Y, Zhang G, Ruan C, Saito K, Song KS, Yoon HJ, Kamiya T, Saito H. Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome). Blood 2001; 97: 1147-9.
9. Franke JD, Montague RA, Kiehart DP. Nonmuscle myosin II generates forces that transmit tension and drive contraction in multiple tissues during dorsal closure. Curr Biol 2005; 15: 2208-21.
10. Paterson HF, Self AJ, Garrett MD, Just I, Aktories K, Hall A. Microinjection of recombinant p21rho induces rapid changes in cell morphology. J Cell Biol 1990; 111: 1001-7.
11. van Leeuwen FN, van Delft S, Kain HE, van der Kammen RA, Collard JG. Rac regulates phosphorylation of the myosin-II heavy chain, actinomyosin disassembly and cell spreading. Nat Cell Biol 1999; 1: 242-8.
12. Seri M, Pecci A, Di Bari F, Cusano R, Savino M, Panza E, Nigro A, Noris P, Gangarossa S, Rocca B, Gresele P, Bizzaro N, Malatesta P, Koiviso PA, Longo I, Musso R, Pecoraro C, Iolascon A, Magrini U, Rodriguez Soriano J, et al. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 2003; 82: 203-15.
13. Pecci A, Panza E, Pujol-Moix N, Klersy C, Di Bari F, Bozzi V, Giesele P, Lethagen S, Fabris F, Dufour C, Granata A, Doubek M, Pecoraro C, Koivis PA, Heller PG, Iolascon A, Alvisi P, Schwabe D, De Candia E, Rocca B, et al. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat 2008; 29: 409-17.
14. Noris P, Spedini P, Belletti S, Magrini U, Balduini CL. Thrombocytopenia, giant platelets, and leukocyte inclusion bodies (May-Hegglin anomaly): Clinical and laboratory findings. Am J Med 1998; 104: 355-60.
15. Canobbio I, Noris P, Pecci A, Balduini A, Balduini CL, Torti M. Altered cytoskeleton organization in platelets from patients with MYH9-related disease. J Thromb Haemost 2005; 3: 1026-35.
16. Pecci A, Canobbio I, Balduini A, Stefanini L, Cisterna B, Marseglia C, Noris P, Savoia A, Balduini CL, Torti M. Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations. Hum Mol Genet 2005; 14: 3169-78.
17. Godwin HA, Ginsburg AD. May-Hegglin anomaly: A defect in megakaryocyte fragmentation? Br J Haematol 1974; 26: 117-21.
18. Italiano JE, Lecine P, Shivdasani RA, Hartwig JH. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol 1999; 147: 1299-312.
19. Chen Z, Naveiras O, Balduini A, Mammoto A, Conti MA, Adelstein RS, Ingber D, Daley GQ, Shivdasani RA. The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway. Blood 2007; 110: 171-9.
20. Conti MA, Even-Ram S, Liu C, Yamada KM, Adelstein RS. Defects in cell adhesion and the visceral endoderm following ablation of nonmuscle myosin heavy chain II-A in mice. J Biol Chem 2004; 279: 41263-6.
21. Leon C, Eckly A, Hechler B, Aleil B, Freund M, Ravanat C, Jourdain M, Nonne C, Weber J, Tiedt R, et al. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. Blood 2007; 110: 3183-91.
22. Eckly A, Strassel C, Freund M, Cazenave JP, Lanza F, Gachet C, Leon C. Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation. Blood 2009; 113: 4-9.
23. Clemetson KJ, McGregor JL, James E, Dechavanne M, Luscher EF. Characterization of the platelet membrane glycoprotein abnormalities in Bernard-Soulier syndrome and comparison with normal by surface-labeling techniques and high-resolution two-dimensional gel electrophoresis. J Clin Invest 1982; 70: 304-11.
24. Marigo V, Nigro A, Pecci A, Montanaro D, Di Stazio M, Balduini CL, Savoia A. Correlation between the clinical phenotype of MYH9-related disease and tissue distribution of class II nonmuscle myosin heavy chains. Genomics 2004; 83: 1125-33.
25. Franke JD, Dong F, Rickoll WL, Kelley MJ, Kiehart DP. Rod mutations associated with MYH9-related disorders disrupt nonmuscle myosin-IIA assembly. Blood 2005; 105: 161-9.
26. Lichtman MA, Chamberlain JK, Simon W, Santillo PA. Parasinusoidal location of megakaryocytes in marrow: A determinant of platelet release. Am J Hematol 1978; 4: 303-12.
27. Junt T, Schulze H, Chen Z, Massberg S, Goerge T, Krueger A, Wagner DD, Graf T, Italiano JE Jr, Shivdasani RA, von Andrian UH. Dynamic visualization of thrombopoiesis within bone marrow. Science 2007; 317: 1767-70.
28. Sabri S, Foudi A, Boukour S, Franc B, Charrier S, Jandrot-Perus M, Farndale RW, Jalil A, Blundell MP, Cramer EM, Louache F, Debili N, Thrasher AJ, Vainchenker W. Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. Blood 2006; 108: 134-40.
29. Chang Y, Aurade F, Larbret F, Zhang Y, Le Couedic JP, Momeux L, Larghero J, Bertoglio J, Louache F, Cramer E, et al. Proplatelet formation is regulated by the Rho/ROCK pathway. Blood 2007; 109: 4229-36.
30. Schulze H, Shivdasani RA. Molecular mechanisms of megakaryocyte differentiation. Semin Thromb Hemost 2004; 30: 389-98.
31. Sabri S, Jandrot-Perrus M, Bertoglio J, Farndale RW, Mas VM, Debili N, Vainchenker W. Differential regulation of actin stress fiber assembly and proplatelet formation by alpha2beta1 integrin and GPVI in human megakaryocytes. Blood 2004; 104: 3117-25.
32. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K, Lin DK, Dias S, Zhang F, Hartman TE, Hackett NR, Crystal RG, Witte L, Hicklin DJ, Beilen P, Eaton D, Lyden D, de Sauvage F, Rafii S. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 2004; 10: 64-71.
33. Berthebaud M, Riviere C, Jarrier P, Foudi A, Zhang Y, Compagno D, Galy A, Vainchenker W, Louache F. RGS16 is a negative regulator of SDF-1-CXCR4 signaling in megakaryocytes. Blood 2005; 106: 2962-8.
34. Arakawa Y, Bito H, Furuyashiki T, Tsuji T, Takemoto-Kimura S, Kimura K, Nozaki K, Hashimoto N, Narumiya S. Control of axon elongation via an SDF-1alpha/Rho/mDia pathway in cultured cerebellar granule neurons. J Cell Biol 2003; 161: 381-91.